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Abstract
Background: Human metapneumovirus (hMPV), a recently identified virus, causes acute respiratory tract infections
(ARTIs) in infants and children. However, studies on the seroepidemeology of hMPV are very limited in China. To
assess the seroprevalence of hMPV infection in China, we tested a total of 1,156 serum specimens for the presence
of anti-hMPV IgG antibody in children and adults free of acute respiratory illness in Beijing, China by using hMPV
nucleocapsid (N) protein as an antigen. As a control, we used the human serum antibody against the N protein of
human respiratory syncytial virus (hRSV), the most important viral agent responsible for ARIs in children.
Results: The seropositive rate for hMPV increased steadily with age from 67% at 1-6 mo to 100% at age 20.
However, the rate dropped slightly between 6 mo and 1 yr of age. The seropositive rate for hRSV also increased
steadily with age from 71% at 1-6 mo to 100% at age 20. In children aged six months to six years, the seropositive
rates for the anti-hRSV IgG antibody were significantly higher than those for hMPV. Additionally, IgG antibody titers
to hMPV and hRSV were significantly higher in adults than in young children. Consistent with the seropositive
rates, the geometric mean titer of anti-hMPV IgG antibody was lower than that of anti-hRSV IgG antibody in
children aged six months to six years.
Conclusions: Our results indicate that similar to hRSV, exposure to hMPV is ubiquitous in the Beijing population.
However, the seroprevalence of anti-hMPV IgG antibody is lower than that of hRSV in children between six months
and six years old, which suggests a different number of repeat infections or a different response to infections.
Background
Human metapneumovirus (hMPV), thought to belong to
the Metapneumovirus genus of the Pneumovirinae sub-
family, is a recently identified human respiratory patho-
gen first isolated from hospitalized children with acute
respiratory infections (ARIs) in the Netherlands [1]. The
viral genome, clinical manifestations, and epidemiology
associated with hMPV are similar to those of human
respiratory syncytial virus (hRSV), which was identified
in 1956 and is the most important viral agent responsi-
ble for ARIs in children [2-4].
Since its initial identification, hMPV infections have
been reported worldwide. However, fluctuating inci-
dence of its infection has been reported by groups from
different areas, varying from 2.2% to 43% in respiratory
tract samples from patients with ARIs [5-16]. Seroepide-
miological investigations also showed that the preva-
lence of hMPV may differ between geographical
locations. For example, in the Netherlands, virtually all
children have been exposed to hMPV by the age of five,
demonstrating that hMPV infection is common in child-
hood [1]. In Canada, an ELISA-based test using recom-
binant nucleocapsid protein (N protein) of hMPV
produced by baculovirus revealed that more than 90% of
patients over 16 years of age tested seropositive for
h M P V[ 1 7 ] .I nC h i n a ,h o w e v e r , studies on the seroepi-
demeology of hMPV have been limited, and it is unclear
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groups have been infected with the virus.
The N protein, about 394 amino acids in length, is
encoded by the N gene of hMPV genome. The hMPV N
protein is abundantly expressed during the early replica-
tion stage of the virus and can stimulate a sustained
immune response [18]. Because the amino acid identity
of hMPV N is highly conserved within and between the
A and B subgroups of hMPV [19], it has been widely
applied in the immunoassay of hMPV infection and in
the investigation of seroprevalence of hMPV infections
[17,18]. hMPV N protein shares 42-44% homology of
amino acid sequence with hRSV [19]. As previous stu-
dies have not shown obvious cross-reactions in immu-
noassays such as ELISA, the hRSV N protein has been
used as a reference to evaluate the seroprevalence of
hMPV [18,20].
To assess the seroprevalence of hMPV infection in
China, we used hMPV N protein as an antigen to test
serum samples for the presence of anti-hMPV IgG anti-
body in children and adults free of acute respiratory ill-
ness in Beijing, China. The IgG antibody against N
protein of hRSV was tested in parallel as a control. Our
results indicate that exposure to hMPV is ubiquitous in
the Beijing population. Lower seropositive rates and
geometric mean titer (GMT) of anti-hMPV IgG were
observed in children aged six months to six years when
compared to hRSV. This may reflect the divergence of
infection pattern between hMPV and hRSV in children.
Our data will inform the evaluation of the social and
economic burden of hMPV infection and enable the
development of medical or public health strategies to
combat hMPV infection in the population.
Results
Establishment of an ELISA-based detection method for
seroprevalence of hMPV and hRSV IgG antibody
Both recombinant hMPV and hRSV N proteins were
effectively expressed in E. coli BL21 (DE3) as soluble
proteins. Recombinant hMPV N protein was then puri-
fied from BL21 (DE3) cell lysates by Ni-chelating chro-
matography, and recombinant hRSV N protein was
purified by anion exchange chromatography followed by
Ni-chelating chromatography (data not shown). The
purity of both recombinant N proteins was greater than
90%. The purified proteins were confirmed by Western
blot analysis using mouse anti-6×His tag monoclonal
a n t i b o d ya st h ep r i m a r ya n t i b o d ya n dI R D y e6 8 0g o a t
anti-mouse monoclonal antibody as the secondary anti-
body (Figure 1).
To optimize ELISA conditions, we performed chess-
board titration tests using the recombinant hMPV and
hRSV N proteins. hMPV-positive and negative sera sam-
ples were identified by Western blot analysis (Figure 2A,
left panel). The optimal antigen (hMPV N protein) con-
centration for ELISA under our test conditions was
determined to be 0.25 μg/ml for hMPV, because at a
1:200 serum dilution, the OD450 nm value of positive
sera was approximately 1.0 and the difference between
the OD450 nm value of positive and negative sera was
greatest (Figure 2A, right panel). Similarly, we deter-
mined the optimal assay conditions for hRSV N protein-
ELISA to be 0.125 μg/ml hRSV N protein at 1:200
serum dilution (Figure 2B).
Based on these ELISA conditions, we then determined
the cut-off value for these assays. Twenty-eight anti-
hMPV IgG negative and 20 anti-hRSV IgG negative sera
samples were identified using Western blot analysis of
100 sera samples randomly collected from children
under five years of age. The OD450 nm of each negative
sample was determined by ELISA for hMPV N protein
or hRSV N protein. The mean value of the OD450 nm of
the hMPV negative sera was 0.24 with a standard devia-
tion (SD) of 0.033. The mean value of the OD450nm of
the hRSV negative sera was 0.261 with a SD of 0.034.
Based on the formula: cut-off value = mean OD450 nm
of the negative sera + three fold SDs [21,22], the hMPV
and hRSV positive cut-off values were then defined as
0.339 and 0.363. A tested sample was scored as “posi-
tive” if its OD450 nm value was above the cut-off value.
The sensitivity of these two ELISA methods was deter-
mined using purified murine IgG against hMPV
or hRSV N proteins. The limits of detection were
0.0625 μg/ml IgG and 0.125 μg/ml IgG, respectively.
To test the specificity of the ELISA methods estab-
lished in this study, the reactions of mouse sera against
influenza virus A (subtypes H1-H16), human corona-
viruses (229E, HKU1 and NL63), and polyomavirus JC
against hMPV and hRSV N protein were evaluated.
There was no obvious cross-reaction between those
mouse antibodies and the hMPV or hRSV N proteins
(data not shown). Furthermore, we did not observe
cross-reaction between the hRSV N protein and hMPV
N protein (data not shown).
Seropositive rates of hMPV and hRSV
For large-scale ELISA screening, each of the tested
serum samples was evaluated for the presence of anti-
hMPV and anti-hRSV (N protein) antibodies. Our analy-
sis indicates that among the 1,156 samples, 67% (28/42)
of subjects aged 1-6 mo, 59% (34/58) of subjects aged
6 mo-1 yr, 76% (65/85) aged 1-3 yr, 85% (79/93) aged
3-6 yr, 98% (119/122) aged 6-20 yr, and 100% (756/756)
aged 20-80 yr were seropositive for hMPV; whereas 71%
(30/42) of subjects aged 1-6 mo, 84% (49/58) aged
6 mo-1 yr, 89% (76/85) aged 1-3 yr, 96% (89/93) aged
3-6 yr, 98% (119/122) aged 6-20 yr, and 100% (756/756)
aged 20-80 yr were seropositive for hRSV (Figure 3 and
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Page 2 of 10Table 1). Comparison between the hMPV and hRSV-
positive sera by statistical analysis (c
2 tests) demonstrated
that the seropositive rates of hMPV were significantly
lower than those of hRSV in the age groups of six
months to six years, whereas no significant difference
was observed in the age groups of one to six months, or
six years to 80 years (Table 1).
Titer of anti-hMPV and anti-hRSV IgG antibodies
To characterize the seroprevalence of hMPV infection in
the sample used in this study further, we analyzed the
titers of anti-hMPV and anti-hRSV IgG antibodies in
our samples. Twenty randomly selected seropositive
samples in each age group were analyzed. The geometric
mean titers (GMTs) of anti-hMPV IgG and anti-hRSV
IgG were significantly higher in the age group of >20
years than in the age group of ≤20 years (for GMT of
anti-hMPV IgG, 556 vs 2599, P = 0.000; for anti-hRSV
IgG, 811 vs 2160, P = 0.000, Mann-Whitney U test)
(Figure 4). Consistent with the seropositive rates, the
GMT of anti-hMPV IgG (481) was also lower than that
of anti-hRSV IgG (857) in a younger group between six
months and six years of age (Mann-Whitney U test, P =
0.005). In this age group, the proportion of specimens
with a low anti-hMPV IgG titer (≤1:400) was signifi-
cantly higher than those with a low anti-hRSV IgG titer
(71.6% vs 48.3%, c
2 test, P = 0.009) (Figure 5). Notably,
for individuals over six years of age, the proportion of
specimens with a high anti-hMPV titer (≥1:3200)
increased and was comparable to those with a high anti-
hRSV IgG titer (56.25% vs 53.75%, c
2 test, P =0 . 7 5 1 )
(Figures 4 and 5).
Discussion
In this report, we show a high seroprevalence of anti-
hMPV IgG antibody in the Beijing area. The 1,156
serum samples included in our study were randomly
collected in 2008, from individuals receiving routine
physical examinations and who were free of recent
respiratory infections. Thus, our data should represent
the incidence of hMPV infection in Beijing. Our results
indicate that virtually all children over the age of six
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Figure 1 Expression and purification of hMPV and hRSV N proteins. His-tagged N proteins from E. coli BL21 (DE3) cell lysates or purified N
proteins were examined by SDS-PAGE (upper panels) and Western blot analysis (bottom panels). Arrows indicate N protein bands and the
bands detected by anti-His monoclonal antibody (Panel A, lane 3, 4; Panel B, lane 3, 4, 5). (A) Expression and purification of hMPV N protein.
Lane 1, total protein extracted from E. coli BL21 (DE3) transformed with pET30a (+); lane 2, supernatant fraction from E. coli BL21 (DE3)
transformed with pET-30a(+)-hMPV-N without IPTG induction; lane 3, supernatant fraction from E. coli BL21 (DE3) transformed with pET-30a
(+)-hMPV-N induced by IPTG; lane 4, purified 6×His-tagged hMPV-N protein. (B) Expression and purification of hRSV N protein. Lane 1, total
protein extracted from E. coli BL21 (DE3) transformed with pET30a (+); lane 2, supernatant fraction from E. coli BL21 (DE3) transformed with pET-
30a(+)-hRSV-N without IPTG induction; lane 3, supernatant fraction from E. coli BL21 (DE3) transformed with pET-30a(+)-hRSV-N induced by IPTG;
lane 4, hRSV-N protein purified using HisTrap Q FF column; lane 5, hRSV-N protein purified using HisTrap HP column. Lane M, molecular protein
markers.
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Page 3 of 10years have been exposed to hMPV infection. Compared
to reports from the Netherlands and Japan in which 192
and 142 samples were tested [1,23], our data were
derived from a larger number of subjects. Consistent
with those two reports, our results suggest that hMPV
infection is ubiquitous. However, our results showed a
higher rate of hMPV infection in infants and younger
children than reported in the Netherlands or Japan.
We found that the seroprevalence of hMPV in children
aged 6 mo to 1 yr was 59% compared to 25% in the
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Figure 2 Screening of hMPV or hRSV-specific IgG positive and negative human sera samples. Examples of samples that are positive or
negative for hMPV or hRSV. (A) Screening of hMPV positive and negative sera samples. Left, Western blot analysis was used to show the
expression of hMPV N protein in positive sera (#221, #308, #471, #365, #199) and negative sera (#21, #75, #92, #99, #108). Right, two-fold serial
dilutions of positive sera (#221, #308, #471, #365, #199) and negative sera (#21, #75, #92, #99, #108) were tested in plates coated with purified
hMPV N protein as described in Methods section. (B) Screening of hRSV positive and hRSV negative sera samples. Left, Western blot analysis was
used to show the expression of hRSV N protein in positive sera (#596, #112, #267, #126, #260) and negative sera (#34, #99, #100, #150, #207).
Right, two-fold serial dilutions of positive sera (#596, #112, #267, #126, #260) and negative sera (#34, #99, #100, #150, #207) were tested in plates
coated with purified hRSV N protein as described in Methods section. Arrows indicate positive bands.
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Page 4 of 10Netherlands and 17.7% in Japan. Thus, our data suggests
that primary infection of children by hMPV may occur
much earlier in Beijing than in the Netherlands or
Japan. This discrepancy may be caused by differences in
exposure to hMPV in different geographical regions, or
by other factors such as social, environmental, or cli-
mate conditions.
Similarly, hRSV has a high seroprevalence rate in Beijing.
Our data correlate with previous findings that seroprevalence
increases with age and that by the age of three, over 90%
of children are seropositive for hRSV [24]. Interestingly,
our results demonstrate that the seropositive rate of
hMPV in children six months to six years of age are signif-
icantly lower than seropositive rates of hRSV (P < 0.05),
suggesting that hRSV infection occurs earlier than hMPV
infection.
Our results showed that the seropositivity of hMPV
decreases during the 6 mo-1 year period. Maternal anti-
bodies may be responsible for higher hMPV seropositiv-
ity in individuals 1-6 months old. The seropositivity of
hMPV decreases during the 6 mo-1 year period as the
level of the maternal antibody decreases. The antibody
titers then increase with age, after repeat hMPV
infection.
Notably, within the age group of 6 mo to 6 yr, the
GMTs of anti-hMPV IgG were significantly lower than
those of anti-hRSV IgG. Significantly more specimens
had a low anti-hMPV IgG (≤1:400) titer than had a low
anti-hRSV IgG titer. The reasons for this disparity are
unclear. It is possible that infection by hMPV occurs
later than infection by hRSV, thus leading to the delayed
increase in the seropositive rate and antibody titer of
hMPV [25]. It is likely that less response to hMPV or
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Figure 3 Seroprevalence of IgG antibodies against hMPV and hRSV. A total of 1,156 serum specimens were tested. Anti-hMPV and anti-
hRSV IgG antibodies were detected using the N-ELISA method (see Methods) at a dilution of 1:200. All serum samples were grouped based on
age, as indicated at the bottom of each panel. The percentage of positive samples in each group is listed above each data point.
Table 1 Age Seropositivity Profiles of hMPV and hRSV
hMPV hRSV
Age % positive
(no. positive/no. tested)
% positive
(no. positive/no. tested)
1-6 mo 67 (28/42) 71(30/42)
6 mo-1 yr 59 (34/58)* 84 (49/58) *
1-3 yr 76 (65/85)* 89 (76/85) *
3-6 yr 85 (79/93)* 96 (89/93) *
6-20 yr 98 (119/122) 98 (119/122)
20-40 yr 100 (248/248) 100 (248/248)
40-60 yr 100 (328/328) 100 (328/328)
60+ yr 100 (180/180) 100 (180/180)
* P < 0.05, by c
2 test.
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Page 5 of 10more exposure to hRSV that would boost the antibody
titer, results in a higher antibody titer against hRSV
than against hMPV. However, large-scale investigations
using samples collected from different geographic
regions are necessary to distinguish the immunological
responses to the two viruses during early human life.
We did not find significant differences between the ser-
oprevalence of hMPV and hRSV infections in children
less than six months of age. This reflects high levels of
maternal antibody against hMPV and hRSV, which may
A                             hMPV 
B                               hRSV 
Figure 4 Titers of anti-hMPV and anti-hRSV IgG antibodies. Twenty human serum samples that were seropositive for hMPV (A) or hRSV
(B) were randomly selected from each age group, for a total of 160 samples. ELISA was performed using hMPV N protein or hRSV N protein as
the antigen. Titers are shown for the indicated age groups. Horizontal bars indicate the GMTs of antibodies against hMPV or hRSV.
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Page 6 of 10be attributed to the high prevalence of antibodies in
adults (Table 1, Figure 3 and 4).
To determine the specificity of our ELISA method, we
tested for reactions between hMPV or hRSV N protein
and murine antibodies against multiple viruses, includ-
ing influenza A viruses (H1-H16), human coronaviruses
(229E, HKU1, NL63) and polyomavirus JC. We found
no obvious reactivity in ELISA assays. Additionally, we
did not detect a cross-reaction between hMPV N pro-
tein and hRSV N protein. These results indicate that the
N protein-based ELISA specifically detects both anti-
hMPV and anti-hRSV antibodies. However, we need to
further evaluate the specificity of the N protein-based
ELISA by using antibodies against other respiratory
virus antigens. The sensitivity of the ELISA method for
detecting hMPV and hRSV was determined by using
purified murine specific anti-hMPV or hRSV N IgG,
respectively. To our knowledge, limits of detection com-
parable to the sensitivity achieved by our methods have
not been reported in other serological surveys of hMPV.
Repeated infections of an individual by hMPV and
hRSV have been reported [26-29], suggesting that
immunity against hMPV and hRSV is not solid, is tran-
sient, or is incomplete against heterologous strains. The
high prevalence and high titers of hMPV and hRSV that
we observed in adults may suggest that re-infection by
hMPV and hRSV occurs throughout life [23,30].
Conclusions
Our results suggest that similar to hRSV infection,
hMPV infection is ubiquitous in the Beijing population.
However, the seroprevalence of the IgG antibody against
hMPV is lower than that against hRSV in children
between six months and six years of age, which may
reflect differences in infection pattern between the two
viruses. Our findings provide further information to aid
the development of strategies to control and prevent
hMPV infection.
Methods
Expression and purification of recombinant hMPV and
hRSV N proteins
Viral RNAs from a nasopharyngeal swab sample positive
for hMPV (#1963) or RSV-B-N (#1949) were extracted.
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Figure 5 Proportions of tested serum samples with different titers of anti-hMPV and anti-hRSV antibodies within different age groups.
Cumulative percentages of anti-hMPV and anti-hRSV antibodies detected in samples from each age group. The percentage of samples with
corresponding titers of anti-hMPV and anti-hRSV IgG antibodies are indicated by different colors defined in the figure key. Titers are expressed as
the reciprocal of the fold dilution. A total of 160 human serum samples that were seropositive for hMPV or hRSV were randomly selected for
ELISA using hMPV N protein or hRSV N protein as the antigen. M, hMPV; R, hRSV.
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into pET30a (+) containing a 6×His tag downstream of a
T7 promoter (Novagen, Wisconsin, USA). These recombi-
nant constructs were transformed into E. coli BL21 (DE3)
(Novagen), and the transformants were grown in LB med-
ium containing 50 μg/ml kanamycin at 37°C for 16 hours.
The cells were diluted to 1:100, transferred to fresh LB
medium, and grown at 37°C until the OD600nm reached
0.8. To induce expression of recombinant proteins, cells
were incubated with 1 mM IPTG at 16°C overnight.
hMPV N protein-expressing cells were harvested and cen-
trifuged at 2,500 × g for 15 minutes at 4°C, resuspended in
lysis buffer (20 mM phosphate, 500 mM NaCl, 20 mM
imidazole, pH7.4), and sonicated at 4°C. The lysates were
centrifuged at 30,000 × g for 15 minutes at 4°C. The
supernatant was purified using a HisTrap HP 1 ml column
(GE Healthcare, Waukesha, USA). Cells expressing
the hRSV N protein were harvested by centrifugation at
2,500 × g for 15 minutes at 4°C, resuspended in lysis buffer
(20 mM phosphate at pH7.4), and then sonicated at 4°C.
The lysates were centrifuged at 30,000 × g for 15 minutes
at 4°C. The supernatant was purified using a HisTrap Q
FF 5 ml column (GE Healthcare) followed by a HisTrap
HP 1 ml column (GE Healthcare). The purification of
N proteins was evaluated by 12% SDS-PAGE and optical
density scanning using the Gene Genius Bio-imaging
System (Syngene, Synoptics Ltd. Cambridge. UK). The
yields of purified 6×His-tagged recombinant proteins were
quantified using the Pierce
®BCA Protein Assay Kit
(Thermo Scientific, Rockford, USA).
Serum samples
Serum specimens were collected from 1,156 subjects,
including 400 children (from the Beijing Children’s Hos-
pital) and 756 adults (from the Beijing Blood Center),
during routine physical examinations in 2008. All indivi-
duals were free of acute respiratory infection for at least
three months prior to sampling. All samples were col-
lected after obtaining informed consent either from the
individuals or from the individual’s guardians. The sera
were separated immediately after collection, stored at
-80°C, and inactivated at 56°C for 30 minutes before use.
Western blot analysis
Purified recombinant proteins were separated by 12%
SDS-PAGE and transferred onto a nitrocellulose mem-
brane, as previously described [31]. The membrane was
blocked for two hours in 5% non-fat milk. Mouse anti-
His monoclonal antibody (Sigma, Munich, Germany)
diluted 1:3000 in non-fat milk or serum samples diluted
1:50 in non-fat milk were added, and membranes were
incubated for one hour at room temperature. Mem-
branes were then washed three times with PBS-0.1%
Tween and incubated for one hour at room temperature
with the secondary antibody, IRDye 680 goat anti-
mouse monoclonal antibody (Li-COR Biosciences,
Nebraska, USA) or horseradish peroxidase-conjugated
goat anti-human IgG monoclonal antibody (Sigma,
Munich, Germany). Subsequently, membranes were
washed three times with PBS-0.1% Tween, then devel-
oped using Odyssey (Li-COR Biosciences) or a tetra-
methylbenzidine (TMB) substrate (Thermo Scientific,
Rockford, USA) according to the manufacturers’
instructions.
Enzyme-linked immunosorbent assay (ELISA)
Chessboard titration tests were conducted using positive
and negative serum samples that were randomly
selected. Western blot analysis was used to determine
the optimal concentration of the coated antigen and
serum dilution. Subsequently, 96-well plates (Costar,
Bethesda, USA) were coated with 100 μlo f0 . 2 5μg/ml
purified hMPV N proteins or 0.125 μg/ml purified
hRSV N proteins, in 0.05 M sodium hydrogen carbonate
buffer (pH9.6). Plates were incubated overnight at 4°C,
then blocked with 1% BSA overnight at 4°C and washed
three times with PBS-0.3% Tween. Subsequently, 100 μl
of a 1:200 dilution of serum specimens was added and
i n c u b a t e da t3 7 ° Cf o ro n eh o u r .T h ep l a t e sw e r et h e n
washed six times with PBS-0.3% Tween and incubated
for one hour at 37°C with horseradish peroxidase-conju-
gated goat anti-human IgG (Sigma) diluted 1:40,000.
The plates were washed again six times with the same
solution, and antibodies were detected by adding 100 μl
substrate solutions A and B (Wantai Biotech Corp. Beij-
ing, China) followed by incubation at 37°C for 10 min-
utes. The reactions were terminated by adding 50 μlo f
2MH 2SO4. Optical densities (OD) were read at
450 nm (OD450 nm). The average OD values for the
hMPV-negative human sera samples (n = 28), shown to
be negative by Western blot analysis for the hMPV-N
protein, were measured. The average OD values of the
hRSV-negative human sera samples (n = 20), shown to
be negative by Western blot analysis for the hRSV-N
protein, were also measured. The cut-off values were
defined as the mean OD of the negative sera plus three
standard deviations [21,22]. Samples with OD450 nm
values above the cut-off value were considered positive.
To determine the specificity of our ELISA method, we
tested mouse sera against inflenza virus HA proteins
(subtype H1-H16), human coronavirus (229E, HKU1,
NL63) N proteins, and polyomavirus JC VP1 protein for
reaction against hMPV and hRSV proteins. Samples of
sera were tested in serial dilutions of two-fold, starting
at a 1:1000 dilution.
To determine the sensitivity of ELISA method estab-
lished in this study, mice sera against hMPV N protein
and hRSV N protein were purified using protein-G
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Page 8 of 10sepharose column (GE Healthcare) and quantified using
Pierce
®BCA Protein Assay Kit (Thermo Scientific, Rock-
ford). The purified murine IgG against hMPV or hRSV
were tested in serial dilutions of two-fold (starting at as
1 μg/ml concentration).
In addition, 20 randomly selected positive serum sam-
ples in each group were subjected to anti-hMPV and
anti-hRSV titer assays. To determine the endpoints of
antibody titers, titers were calculated as the highest dilu-
tion of a serum showing an OD450 nm reading of two
times the mean of the negative serum control (starting
at a 1:50) [32].
Statistical analysis
Seropositive rates were evaluated using c2 tests. Mean
antibody titers between children and adults positive for
hMPV and hRSV exposure were analyzed using the
Mann-Whitney U test. A P value ≤ 0.05 was considered
statistically significant.
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